FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950761310> ?p ?o ?g. }

• W2950761310 abstract "Treatment options for the management of moderate to severe plaque psoriasis include phototherapy, oral systemic agents, and biologic therapy. Secukinumab, a fully human monoclonal antibody that selectively targets IL-17A, is the first IL-17 antagonist approved for this patient population. Long-term observational data are required for establishing the true population-based benefit-risk ratio of approved treatments. PURE is a multinational registry that will assess the real-world safety and effectiveness of secukinumab and other approved therapies in the management of patients with moderate to severe psoriasis.This is a multinational (Canadian and Latin American), prospective, observational study of adult patients with moderate to severe psoriasis that initiate treatment with secukinumab or other approved therapies as per local standard of care. A total of 2500 patients (1250 per cohort) will be recruited in the practices of hospital and community dermatologists. Decision regarding treatment must have been reached prior to and independent of patient enrollment in the study. The study includes a 5-year follow-up with recommended assessments at Baseline, 3 and 6 months post-Baseline, and every 6 months thereafter. The primary objective of the study is safety. Secondary outcome measures relate to effectiveness (Investigator's Global Assessment -IGA mod 2011-, Psoriasis Areas and Severity Index, Body Surface Area), patient reported outcomes (Dermatology Life Quality Index, Work Productivity and Activity Impairment Questionnaire, Hospital Anxiety and Depression Scale, Psoriasis Epidemiology Screening Tool, Psoriasis Symptom Diary, and Treatment Satisfaction Questionnaire), and healthcare resource utilization.This is the first observational study in Canada and Latin America assessing the real-world safety and effectiveness of secukinumab in the management of moderate to severe psoriasis. The extensive clinical, patient-reported and health economic outcomes collected will allow the comprehensive evaluation of this new treatment in comparison to other approved therapies.ClinicalTrials.gov Identifier: NCT02786186 ; date of registration: May 30, 2016." @default.
• W2950761310 created "2019-06-27" @default.
• W2950761310 creator A5006526834 @default.
• W2950761310 creator A5008286260 @default.
• W2950761310 creator A5010125501 @default.
• W2950761310 creator A5011569251 @default.
• W2950761310 creator A5013896979 @default.
• W2950761310 creator A5021906179 @default.
• W2950761310 creator A5025168881 @default.
• W2950761310 creator A5040311529 @default.
• W2950761310 creator A5063500958 @default.
• W2950761310 creator A5065774384 @default.
• W2950761310 creator A5073434897 @default.
• W2950761310 creator A5086788918 @default.
• W2950761310 creator A5091771735 @default.
• W2950761310 date "2019-06-21" @default.
• W2950761310 modified "2023-10-04" @default.
• W2950761310 title "Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America" @default.
• W2950761310 cites W1990882766 @default.
• W2950761310 cites W2056996834 @default.
• W2950761310 cites W2062964437 @default.
• W2950761310 cites W2073501077 @default.
• W2950761310 cites W2080165152 @default.
• W2950761310 cites W2107196215 @default.
• W2950761310 cites W2121126920 @default.
• W2950761310 cites W2317308047 @default.
• W2950761310 cites W2463021530 @default.
• W2950761310 doi "https://doi.org/10.1186/s12895-019-0087-3" @default.
• W2950761310 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6588885" @default.
• W2950761310 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31226985" @default.
• W2950761310 hasPublicationYear "2019" @default.
• W2950761310 type Work @default.
• W2950761310 sameAs 2950761310 @default.
• W2950761310 citedByCount "6" @default.
• W2950761310 countsByYear W29507613102019 @default.
• W2950761310 countsByYear W29507613102020 @default.
• W2950761310 countsByYear W29507613102022 @default.
• W2950761310 crossrefType "journal-article" @default.
• W2950761310 hasAuthorship W2950761310A5006526834 @default.
• W2950761310 hasAuthorship W2950761310A5008286260 @default.
• W2950761310 hasAuthorship W2950761310A5010125501 @default.
• W2950761310 hasAuthorship W2950761310A5011569251 @default.
• W2950761310 hasAuthorship W2950761310A5013896979 @default.
• W2950761310 hasAuthorship W2950761310A5021906179 @default.
• W2950761310 hasAuthorship W2950761310A5025168881 @default.
• W2950761310 hasAuthorship W2950761310A5040311529 @default.
• W2950761310 hasAuthorship W2950761310A5063500958 @default.
• W2950761310 hasAuthorship W2950761310A5065774384 @default.
• W2950761310 hasAuthorship W2950761310A5073434897 @default.
• W2950761310 hasAuthorship W2950761310A5086788918 @default.
• W2950761310 hasAuthorship W2950761310A5091771735 @default.
• W2950761310 hasBestOaLocation W29507613101 @default.
• W2950761310 hasConcept C126322002 @default.
• W2950761310 hasConcept C159110408 @default.
• W2950761310 hasConcept C16005928 @default.
• W2950761310 hasConcept C1862650 @default.
• W2950761310 hasConcept C23131810 @default.
• W2950761310 hasConcept C2776173921 @default.
• W2950761310 hasConcept C2776260265 @default.
• W2950761310 hasConcept C2777011040 @default.
• W2950761310 hasConcept C2779786854 @default.
• W2950761310 hasConcept C2779951463 @default.
• W2950761310 hasConcept C2780564577 @default.
• W2950761310 hasConcept C2781427535 @default.
• W2950761310 hasConcept C2908647359 @default.
• W2950761310 hasConcept C71924100 @default.
• W2950761310 hasConcept C99454951 @default.
• W2950761310 hasConceptScore W2950761310C126322002 @default.
• W2950761310 hasConceptScore W2950761310C159110408 @default.
• W2950761310 hasConceptScore W2950761310C16005928 @default.
• W2950761310 hasConceptScore W2950761310C1862650 @default.
• W2950761310 hasConceptScore W2950761310C23131810 @default.
• W2950761310 hasConceptScore W2950761310C2776173921 @default.
• W2950761310 hasConceptScore W2950761310C2776260265 @default.
• W2950761310 hasConceptScore W2950761310C2777011040 @default.
• W2950761310 hasConceptScore W2950761310C2779786854 @default.
• W2950761310 hasConceptScore W2950761310C2779951463 @default.
• W2950761310 hasConceptScore W2950761310C2780564577 @default.
• W2950761310 hasConceptScore W2950761310C2781427535 @default.
• W2950761310 hasConceptScore W2950761310C2908647359 @default.
• W2950761310 hasConceptScore W2950761310C71924100 @default.
• W2950761310 hasConceptScore W2950761310C99454951 @default.
• W2950761310 hasIssue "1" @default.
• W2950761310 hasLocation W29507613101 @default.
• W2950761310 hasLocation W29507613102 @default.
• W2950761310 hasLocation W29507613103 @default.
• W2950761310 hasLocation W29507613104 @default.
• W2950761310 hasLocation W29507613105 @default.
• W2950761310 hasLocation W29507613106 @default.
• W2950761310 hasLocation W29507613107 @default.
• W2950761310 hasOpenAccess W2950761310 @default.
• W2950761310 hasPrimaryLocation W29507613101 @default.
• W2950761310 hasRelatedWork W2049806411 @default.
• W2950761310 hasRelatedWork W2285826736 @default.
• W2950761310 hasRelatedWork W2791244279 @default.
• W2950761310 hasRelatedWork W2895404113 @default.
• W2950761310 hasRelatedWork W2923741572 @default.
• W2950761310 hasRelatedWork W2950761310 @default.
• W2950761310 hasRelatedWork W2954778191 @default.
• W2950761310 hasRelatedWork W3045413237 @default.

• next